Yılmaz Ufuk, Kırakli Esra Korkmaz, Gürlek Ümit, Özdoğan Yasemin, Gümüş Bahri, Akşit Salih
Department of Pulmonary Medicine, Dr. Suat Seren Chest Disease and Surgery Training and Research Hospital, İzmir, Turkey.
Department of Radiation Oncology, Dr. Suat Seren Chest Disease and Surgery Training and Research Hospital, İzmir, Turkey.
Turk Thorac J. 2017 Jan;18(1):11-13. doi: 10.5152/TurkThoracJ.2017.16022. Epub 2017 Jan 1.
Prophylactic cranial irradiation (PCI) decreases incidence of brain metastasis and improves survival in patients with limited disease-small cell lung cancer (LD-SCLC) who achieved complete response (CR) after treatment. There is no satisfactory evidence about the necessity of new brain imaging for asymptomatic metastasis immediately prior to PCI. The present study aimed to evaluate the frequency of brain metastasis in SCLC patients without neurological symptoms who are candidates for PCI.
The data files of 243 patients with SCLC referred for cranial irradiation were retrospectively reviewed. The patients with following characteristics were enrolled to the study; 1) LD-SCLC patients with CR after chemoradiotherapy who are candidates for PCI. 2) No neurological signs or symptoms of brain metastasis after chemoradiotherapy. 3) Having brain imaging at initial diagnosis and before PCI.
Ninety-nine patients (83 male, 83.3%) were included in this study. Median age was 60 years. Time interval between initial and reevaluation for brain metastasis was median 5.5 months (range; 4.7-7.1). Asymptomatic brain metastasis rate was 20.2% (18/99).
Even if local disease is under control, asymptomatic brain metastasis is not rare. Therefore, patients who are candidates for PCI after completion of chemoradiotherapy should be reimaged for brain metastasis before PCI.
预防性颅脑照射(PCI)可降低脑转移的发生率,并提高疾病局限期小细胞肺癌(LD-SCLC)患者在治疗后达到完全缓解(CR)时的生存率。对于在PCI前立即进行新的脑成像以检测无症状转移的必要性,目前尚无令人满意的证据。本研究旨在评估适合接受PCI的无神经系统症状的SCLC患者脑转移的发生率。
回顾性分析243例接受颅脑照射的SCLC患者的数据文件。纳入本研究的患者具有以下特征:1)放化疗后达到CR且适合接受PCI的LD-SCLC患者。2)放化疗后无脑转移的神经系统体征或症状。3)在初始诊断时和PCI前进行过脑成像检查。
本研究纳入99例患者(83例男性,占83.3%)。中位年龄为60岁。从初始诊断到重新评估脑转移的时间间隔中位数为5.5个月(范围:4.7 - 7.1个月)。无症状脑转移率为20.2%(18/99)。
即使局部疾病得到控制,无症状脑转移也并不罕见。因此,放化疗完成后适合接受PCI的患者在PCI前应重新进行脑转移成像检查。